Patents by Inventor Philippe Brulet

Philippe Brulet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8263821
    Abstract: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a particular embodiment, said recombinant polypeptide comprises or consists of the Aequorin and GFP linked by a linker allowing chemiluminescence resonance energy transfer (CRET), and optionally comprises a peptidic fragment capable of targeting said recombinant polypeptide into a specific cellular domain or compartment. The present invention also concerns a transgenic non-human animal expressing said recombinant polypeptide sensitive to calcium concentration, in conditions enabling the in vivo monitoring of Ca2+ dynamics.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: September 11, 2012
    Assignee: Institut Pasteur
    Inventors: Philippe Brulet, Kelly Rogers, Sandrine Picaud
  • Patent number: 7923015
    Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.
    Type: Grant
    Filed: April 6, 2004
    Date of Patent: April 12, 2011
    Assignees: Institut Pasteur, Centre Nationale de la Recherche Scientifique
    Inventors: Rafael Vazquez-Martinez, Philippe Brulet
  • Patent number: 7923216
    Abstract: A hybrid protein (GFP-TTC) comprising the non-toxic proteolytic C fragment of tetanus toxin fused to green fluorescent protein was used to analyze the functional synaptic organization of neural networks. When injected intramuscularly in vivo, the GFP-TTC hybrid protein binds to tetanus neurotoxin receptors and clusters very rapidly to the active neuromuscular junction. Membrane traffic by GFP-TTC at the pre-synaptic level of the neuromuscular junction is strongly and rapidly influenced by exogenously co-injecting neurotrophic factors, such as BDNF, NT-4, and GDNF, but not by NGF, NT-3, and CNTF. The membrane traffic, directly detected using GFP-TTC in vivo, permits methods of analyzing synaptic functioning as well as methods of modulating neuronal transport using neurotrophic factors and agonists or antagonists thereof.
    Type: Grant
    Filed: September 16, 2003
    Date of Patent: April 12, 2011
    Assignees: Institut Pasteur, Centre Nationale de la Recherche Scientifique
    Inventors: Sylvie Roux, Philippe Brulet, Cécile Saint Cloment, Julien Barbier, Jordi Molgo
  • Publication number: 20110002914
    Abstract: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the LacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and ?gal enzymatic activity. After intramuscular injection, enzymatic activity can be detected in motoneurons and connected neurons of brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.
    Type: Application
    Filed: July 7, 2010
    Publication date: January 6, 2011
    Inventors: LAURENT COEN, ROSARIO OSTA PINZOLAS, PHILIPPE BRULET
  • Publication number: 20100330667
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).
    Type: Application
    Filed: June 4, 2010
    Publication date: December 30, 2010
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valérie BAUBET, Hervé Le Mouellic, Philippe Brulet
  • Publication number: 20100260758
    Abstract: The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 14, 2010
    Inventors: Sylvie ROUX, Philippe Brulet, Cecile Saint Cloment, Julien Barbier, Jordi Molgo
  • Publication number: 20100239534
    Abstract: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the IacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and ?-gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.
    Type: Application
    Filed: June 26, 2008
    Publication date: September 23, 2010
    Inventors: Laurent Coen, Rosario Osta Pinzolas, Philippe Brulet
  • Patent number: 7763443
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer(CRET).
    Type: Grant
    Filed: June 10, 2005
    Date of Patent: July 27, 2010
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valérie Baubet, Hervé Le Mouellic, Philippe Brulet
  • Publication number: 20100081197
    Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.
    Type: Application
    Filed: September 14, 2007
    Publication date: April 1, 2010
    Inventors: Sylvie Roux, Philippe Brulet, Cecile Saint Cloment, Julien Barbier, Jordi Molgo
  • Publication number: 20090226468
    Abstract: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the lacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and -gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.
    Type: Application
    Filed: June 21, 2007
    Publication date: September 10, 2009
    Applicant: Institut Pasteur
    Inventors: Laurent Coen, Rosario Osta Pinzolas, Philippe Brulet
  • Publication number: 20080282362
    Abstract: A method for bioluminescence imaging in an animal is provided. The method comprises providing a whole animal containing a transcriptionally active nucleic acid sequence encoding a Ca2+-sensitive polypeptide, which comprises a chemiluminescent protein linked to a fluorescent protein; and monitoring photons emitted by the Ca2+-sensitive polypeptide. The Ca2+-sensitive polypeptide comprises aequorin protein covalently linked to a YFP (yellow fluorescent protein) or RFP (red fluorescent protein), and the link between the two proteins functions to allow luminescence by energy transfer between the two proteins. The photons are monitored from deep tissues of the animal.
    Type: Application
    Filed: August 24, 2006
    Publication date: November 13, 2008
    Inventors: Philippe Brulet, Kelly Rogers, Thomas Curie
  • Patent number: 7435792
    Abstract: The non-toxic proteolytic C fragment of tetanus toxin (TTC peptide) has the same ability to bind nerve cells and be retrogradely transported through a synapse as the native toxin. A hybrid protein encoded by the IacZ-TTC gene fusion retains the biological functions of both proteins in vivo, i.e. retrograde transynaptic transport of the TTC fragment and ?-gal enzymatic activity. After intramuscular injection, enzymatic activity could be detected in motoneurons and connected neurons of the brainstem areas. This strategy is useful for the delivery of a biological activity to neurons from the periphery to the central nervous system. Such a hybrid protein can also be used to map synaptic connections between neural cells.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: October 14, 2008
    Assignee: Institut Pasteur
    Inventors: Laurent Coen, Rosario Osta Pinzolas, Philippe Brulet
  • Publication number: 20080213879
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer(CRET).
    Type: Application
    Filed: June 10, 2005
    Publication date: September 4, 2008
    Applicants: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valerie Baubet, Herve Le Mouellic, Philippe Brulet
  • Publication number: 20080182331
    Abstract: DNA gene inactivation constructs for homologous recombination in the genome of a mammalian cell are provided.
    Type: Application
    Filed: March 13, 2007
    Publication date: July 31, 2008
    Inventors: Herve Le Mouellic, Philippe Brulet
  • Publication number: 20070274923
    Abstract: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a particular embodiment, said recombinant polypeptide comprises or consists of the Aequorin and GFP linked by a linker allowing chemiluminescence resonance energy transfer (CRET), and optionally comprises a peptidic fragment capable of targeting said recombinant polypeptide into a specific cellular domain or compartment. The present invention also concerns a transgenic non-human animal expressing said recombinant polypeptide sensitive to calcium concentration, in conditions enabling the in vivo monitoring of Ca2+ dynamics.
    Type: Application
    Filed: August 4, 2006
    Publication date: November 29, 2007
    Inventors: Philippe Brulet, Kelly Rogers, Sandrine Picaud
  • Publication number: 20070092449
    Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.
    Type: Application
    Filed: October 5, 2006
    Publication date: April 26, 2007
    Inventors: Rafael Vazquez-Martinez, Philippe Brulet
  • Publication number: 20060275327
    Abstract: The invention relates to means for in vivo delivery of a composition into the human or animal central nervous system or spinal cord, wherein the composition comprises a non-toxic, proteolytic fragment of tetanus toxoid in association with at least a molecule having a biological function, and said molecule is capable of in vivo retrograde axonal transport and transynaptic transport into the CNS or spinal cord of the human or animal. In a particular embodiment, the composition comprises a fragment C and a fragment B of tetanus toxoid or a fraction thereof of at least 11 amino acid residues. The composition can further comprise a fraction of fragment A of tetanus toxoid.
    Type: Application
    Filed: March 15, 2006
    Publication date: December 7, 2006
    Inventors: Sylvie Roux, Philippe Brulet, Cecile Cloment, Julien Barbier, Jordi Molgo
  • Publication number: 20050273867
    Abstract: The invention relates to a method for optical detection of the dynamics of Ca2+ in a biological system, said method comprising monitoring the photons emitted by a recombinant Ca2+-sensitive polypeptide, which comprises or consists of a chemiluminescent protein linked to a fluorescent protein, present in said biological system. In a particular embodiment, said recombinant polypeptide comprises or consists of the Aequorin and GFP linked by a linker allowing chemiluminescence resonance energy transfer (CRET), and optionally comprises a peptidic fragment capable of targeting said recombinant polypeptide into a specific cellular domain or compartment. The present invention also concerns a transgenic non-human animal expressing said recombinant polypeptide sensitive to calcium concentration, in conditions enabling the in vivo monitoring of Ca2+ dynamics.
    Type: Application
    Filed: January 11, 2005
    Publication date: December 8, 2005
    Inventors: Philippe Brulet, Kelly Rogers, Sandrine Picaud
  • Patent number: 6936475
    Abstract: A modified bioluminescent system comprising a fluorescent molecule covalently linked with a photoprotein, wherein said link between the two proteins has the function to stabilize the modified bioluminescent system and allowing the transfer of the energy by Chemiluminescence Resonance Energy Transfer (CRET).
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: August 30, 2005
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Valérie Baubet, Hervé Le Mouellic, Philippe Brulet
  • Publication number: 20050060761
    Abstract: A method for visualizing an active synapse wherein said method comprises: (a) exposing cells forming the active synapse to a biomarker comprising at least fragment C of tetanus toxin and a reporter protein; and (b) visualizing the biomarker; wherein the accumulation of the biomarker into dendritic spines of the cells allows visualization of an active synapse. Also, a method for screening molecules capable of modulating synapse activity is provided. A kit useful for the early diagnosis of neurodegenerative disease comprises a biomarker comprising at least fragment C of tetanus toxin and a reporter protein.
    Type: Application
    Filed: April 6, 2004
    Publication date: March 17, 2005
    Inventors: Rafael Vazquez-Martinez, Philippe Brulet